💊Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy
ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) announced that ONO PHARMA TAIWAN CO., LTD. (“OPTW”) received the supplemental approval of Opdivo® Intravenous Infusion 20 mg, 100 mg (Generic name: nivolumab; “Opdivo”), a human anti-human PD-1 (programmed cell death-1) monoclonal antibody, on November 2 from the Taiwan Food and Drug Administration (TFDA) in Taiwan, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.